The U.S. Department of Justice has initiated a criminal investigation into UnitedHealth Group, the nation’s largest health insurer, focusing on potential Medicare fraud tied to its Medicare Advantage business. This probe, active since at least last summer, marks a significant escalation in scrutiny for the company, which has faced multiple federal inquiries in recent years. The investigation comes at a turbulent time for UnitedHealth, with its stock plummeting and leadership undergoing abrupt changes. The healthcare giant’s Medicare Advantage program, serving over 8 million enrollees, is now at the center of federal attention.
This development follows a series of setbacks for UnitedHealth, including a civil investigation into its Medicare billing practices and public backlash after the tragic killing of a top executive. The company’s financial performance has also drawn investor concern, with shares dropping significantly in recent months. The Justice Department’s probe is examining whether UnitedHealth’s practices in its Medicare Advantage plans, which manage government health benefits for seniors, involve fraudulent activities. Key aspects of the investigation include:
- Allegations of inflated diagnoses to secure higher government payments.
- Scrutiny of billing practices at UnitedHealth’s doctors’ offices.
- Potential financial penalties if fraudulent activities are confirmed.
UnitedHealth has publicly denied receiving formal notification of the criminal probe and has defended the integrity of its Medicare Advantage program. The company’s response highlights the complexity of navigating federal regulations in the healthcare sector. As the investigation unfolds, stakeholders are closely watching its potential impact on UnitedHealth’s operations and the broader health insurance industry.
Federal scrutiny intensifies
The Justice Department’s criminal division, specifically its healthcare-fraud unit, is leading the investigation into UnitedHealth’s Medicare Advantage practices. Sources indicate that the probe has been ongoing for months, with investigators delving into whether the company manipulated patient diagnoses to trigger higher payments from the government. This practice, known as upcoding, has long been a concern in the Medicare Advantage program, which relies on private insurers to manage care for millions of seniors.
In February, reports surfaced that the Justice Department was conducting a civil investigation into UnitedHealth’s Medicare billing practices, focusing on similar allegations of inflated diagnoses. That inquiry, combined with the current criminal probe, underscores the government’s growing concern over potential fraud in the Medicare Advantage system. UnitedHealth’s program, which covers more than 8 million Americans, is the largest of its kind, making the stakes particularly high.
The company has faced additional scrutiny from lawmakers, with U.S. Senator Chuck Grassley launching an inquiry into its billing methods earlier this year. Grassley demanded detailed compliance records, signaling bipartisan concern over how private insurers manage Medicare funds. UnitedHealth’s response to these inquiries has been consistent, emphasizing its adherence to federal regulations and the robustness of its compliance programs.
Stock market turmoil
UnitedHealth’s stock has taken a significant hit in recent months, with shares dropping nearly 50% over the past year. On May 15, 2025, the company’s stock fell as much as 17% in early trading, reaching a five-year low of $259.97. This plunge was triggered by a Wall Street Journal report detailing the Justice Department’s criminal investigation. The stock’s decline reflects broader investor unease about UnitedHealth’s financial health and legal challenges.
The company’s financial woes were compounded by its decision to suspend its 2025 earnings guidance earlier this week. UnitedHealth cited rising medical costs, particularly from new Medicare Advantage members, as a key factor in its revised outlook. This move sent shares tumbling 18% on Tuesday, wiping out billions in market value. Investors are now grappling with the uncertainty surrounding the company’s legal and financial future.
- Key financial impacts:
- Stock down 49% year-to-date.
- Market value loss of over $119 billion in April 2025 alone.
- Suspension of 2025 financial forecast due to rising costs.
The combination of legal scrutiny and financial instability has placed UnitedHealth in a precarious position, with analysts warning of potential penalties and reputational damage.
UnitedHealth Group is under criminal investigation by the Justice Department for possible Medicare fraud, WSJ reports. pic.twitter.com/AttfR0pAYu
— Pop Base (@PopBase) May 15, 2025
Leadership shakeup adds to challenges
The abrupt departure of CEO Andrew Witty this week has further fueled uncertainty at UnitedHealth. Witty, who cited personal reasons for his exit, was replaced by Stephen Hemsley, a former longtime chief executive who led the company from 2006 to 2017. Hemsley’s return comes at a critical juncture, as UnitedHealth navigates multiple federal investigations and a volatile stock market.
Witty’s resignation followed a tumultuous period for the company, including the high-profile killing of Brian Thompson, the CEO of its insurance unit, in December 2024. Thompson’s death sparked widespread public frustration with the U.S. healthcare system, with UnitedHealth facing criticism over claim denials and industry practices. The company has since been named in a lawsuit by shareholders, who allege that UnitedHealth downplayed the business impact of Thompson’s killing.
Hemsley’s leadership will be tested as he addresses the ongoing criminal probe and seeks to stabilize the company’s financial performance. His prior experience at UnitedHealth may provide continuity, but the scale of the current challenges is unprecedented.
Medicare Advantage under the microscope
The Medicare Advantage program, which allows private insurers like UnitedHealth to manage Medicare benefits, has grown rapidly in recent years. Over 50% of Medicare-eligible seniors are now enrolled in such plans, drawn by benefits like dental and vision coverage not offered by traditional Medicare. However, the program’s reliance on private insurers has raised concerns about oversight and accountability.
Federal investigators are particularly focused on whether UnitedHealth’s billing practices exploit loopholes in the Medicare Advantage payment system. For example, insurers receive higher payments for patients with more severe diagnoses, creating an incentive to exaggerate medical conditions. The Justice Department’s probe is examining whether UnitedHealth systematically engaged in such practices to boost revenue.
- Medicare Advantage concerns:
- Rapid growth: Over 30 million Americans enrolled by 2025.
- Payment structure: Insurers paid more for sicker patients.
- Oversight gaps: Limited federal audits of billing practices.
The investigation could have far-reaching implications for the Medicare Advantage program, potentially prompting stricter regulations and oversight.
Public and industry reactions
The news of UnitedHealth’s criminal investigation has sparked a range of reactions from stakeholders. Industry analysts have expressed concern about the potential ripple effects on other health insurers, many of which operate similar Medicare Advantage programs. Some warn that increased federal scrutiny could lead to higher compliance costs and reduced profitability across the sector.
Public sentiment, already strained by frustrations with the healthcare system, has been further inflamed by the allegations against UnitedHealth. Social media platforms have seen an outpouring of criticism, with many users citing Thompson’s killing as a symbol of broader dissatisfaction with private insurers. Physicians, too, have voiced concerns, pointing to the administrative burdens and claim denials that characterize the Medicare Advantage system.
UnitedHealth has sought to counter these narratives, emphasizing its commitment to patient care and regulatory compliance. In a statement, the company called the Wall Street Journal’s reporting “deeply irresponsible” and reiterated that it had not been formally notified of the criminal probe.
Broader legal challenges
In addition to the criminal investigation, UnitedHealth faces a civil fraud case alleging that it overcharged the government by more than $2 billion through improper Medicare Advantage billing. This lawsuit, which has been ongoing for years, claims that UnitedHealth manipulated patient data to secure higher payments. The company has denied these allegations, arguing that its practices align with industry standards.
The Justice Department has also filed a separate lawsuit against three major health insurers, accusing them of paying kickbacks to brokers to steer patients into Medicare Advantage plans. While UnitedHealth is not named in this suit, the case highlights the government’s broader crackdown on fraudulent practices in the program.
- Ongoing legal battles:
- Civil fraud case alleging $2 billion in overcharges.
- Antitrust probe over UnitedHealth’s acquisition of Amedisys.
- Shareholder lawsuit over Thompson’s killing.
These legal challenges underscore the complex regulatory environment in which UnitedHealth operates, with potential penalties that could further strain its finances.
Historical scrutiny of billing practices
UnitedHealth’s Medicare Advantage program has faced scrutiny for years, with whistleblowers and regulators raising concerns about its billing practices. In 2017, a whistleblower lawsuit alleged that UnitedHealth engaged in upcoding to inflate Medicare payments, a claim the company denied. More recently, a 2023 report by the Department of Health and Human Services found that Medicare Advantage plans, including UnitedHealth’s, often overstated patient diagnoses to secure higher payments.
The company’s practice of offering gift cards to Medicare Advantage members for nurse visits has also drawn criticism. These visits, intended to assess patient health, have been flagged as opportunities for UnitedHealth to document additional diagnoses, potentially boosting payments. While not illegal, such practices have fueled perceptions of ethical lapses.
The current criminal probe builds on this history, with investigators likely examining patterns of behavior over multiple years. The outcome could set a precedent for how Medicare Advantage plans are regulated moving forward.
Impact on healthcare providers
The investigation into UnitedHealth has raised concerns among healthcare providers, many of whom rely on the company’s Medicare Advantage plans to serve their patients. Hospitals and clinics are bracing for potential disruptions if the probe leads to changes in UnitedHealth’s operations or payment structures. Some providers worry that stricter regulations could reduce reimbursements, squeezing their already tight margins.
Physicians, in particular, have expressed frustration with the administrative complexities of Medicare Advantage plans. The need to document detailed diagnoses to justify higher payments often diverts time from patient care, they argue. If the Justice Department’s probe results in new compliance requirements, providers may face even greater administrative burdens.
- Provider concerns:
- Potential reduction in reimbursements.
- Increased administrative workload.
- Uncertainty about future contracts with UnitedHealth.
These challenges highlight the interconnected nature of the healthcare system, where changes in one area can have cascading effects.
Regulatory landscape shifts
The Justice Department’s focus on UnitedHealth reflects a broader push to address fraud in the Medicare Advantage program. In recent years, federal regulators have stepped up audits of private insurers, uncovering billions in improper payments. A 2024 report by the Government Accountability Office estimated that Medicare Advantage overpayments cost taxpayers $12 billion annually, much of it tied to upcoding.
Lawmakers are also taking action, with proposals to strengthen oversight of Medicare Advantage plans gaining traction in Congress. These efforts aim to balance the program’s benefits, such as expanded coverage options, with the need to protect public funds from abuse. UnitedHealth’s investigation could accelerate these reforms, reshaping the industry’s regulatory landscape.
The company’s competitors, including Humana and Aetna, are likely watching the probe closely, as its outcome could set new standards for compliance and billing. For now, UnitedHealth remains the focal point of federal efforts to curb fraud in the program.
Financial pressures mount
UnitedHealth’s financial challenges extend beyond the stock market. The company reported its first quarterly earnings miss in over a decade in April 2025, citing higher-than-expected medical costs in its Medicare Advantage business. This miss prompted UnitedHealth to lower its 2025 forecast, a decision that rattled investors and contributed to the stock’s decline.
Rising medical costs, driven by an aging population and increased healthcare utilization, have put pressure on UnitedHealth’s margins. The company has also faced higher-than-expected costs from new Medicare Advantage members, who often require more intensive care. These financial strains have raised questions about UnitedHealth’s ability to maintain its dominant position in the market.
Analysts at Mizuho Securities have noted that while the Justice Department’s investigation introduces uncertainty, UnitedHealth’s long-term outlook remains positive. The company expects earnings growth in 2026, driven by improved cost trends and stronger Medicare Advantage rates. However, achieving these goals will require navigating the current legal and financial challenges.
Stakeholder perspectives
The investigation has drawn attention from a wide range of stakeholders, each with distinct concerns. Shareholders are focused on the potential for financial penalties and further stock declines, while patients worry about the implications for their coverage. Advocacy groups, meanwhile, are calling for greater transparency in how Medicare Advantage plans operate.
Physicians and healthcare providers have used the probe as an opportunity to highlight systemic issues in the Medicare Advantage program. Many argue that the program’s payment structure incentivizes insurers to prioritize profits over patient care, a criticism that has gained traction in light of UnitedHealth’s investigation.
UnitedHealth, for its part, has vowed to cooperate with federal authorities while defending its practices. The company’s leadership has emphasized its role in providing affordable care to millions of Americans, a message aimed at reassuring investors and the public.
Industry-wide implications
The Justice Department’s probe into UnitedHealth could have broader implications for the health insurance industry. If the investigation uncovers systemic issues in the Medicare Advantage program, other insurers may face similar scrutiny. This could lead to stricter regulations, higher compliance costs, and changes in how plans are structured.
Smaller insurers, in particular, may struggle to adapt to a more stringent regulatory environment. UnitedHealth’s size and resources give it an advantage in navigating legal challenges, but smaller players may face greater financial strain. The probe could also accelerate consolidation in the industry, as weaker firms seek partnerships to survive.
For now, UnitedHealth remains at the center of the storm, with its actions likely to shape the future of Medicare Advantage. The company’s ability to address the allegations and restore investor confidence will be critical in the months ahead.
